Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BJSE:920199's ROA % is ranked better than 50.53% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.73
vs BJSE:920199: 0.88
SiChuan Qian Li Beoka Medical Technology Co (BJSE:920199) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
SiChuan Qian Li Beoka Medical Technology Co ROA % Related Terms
SiChuan Qian Li Beoka Medical Technology Co ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SiChuan Qian Li Beoka Medical Technology Co ROA % Chart
SiChuan Qian Li Beoka Medical Technology Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SiChuan Qian Li Beoka Medical Technology Co ROA % vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
SiChuan Qian Li Beoka Medical Technology Co (BJSE:920199) has a ROA % of 0.31% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on SiChuan Qian Li Beoka Medical Technology Co and its competitors. This is 97% below median its historical median of 9.40. Over the past decade, SiChuan Qian Li Beoka Medical Technology Co's ROA % has ranged from 0.57 to 54.56. According to the industry distribution chart, SiChuan Qian Li Beoka Medical Technology Co ranks #422 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 49.5%.
Is SiChuan Qian Li Beoka Medical Technology Co's ROA % too high?
SiChuan Qian Li Beoka Medical Technology Co's current ROA % of 0.31% is 97% below median its 10-year median of 9.40. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 54.56. The Medical Devices & Instruments industry median ROA % is 0.73. SiChuan Qian Li Beoka Medical Technology Co's value of 0.31% is 57.5% below this industry median. Based on the distribution chart, SiChuan Qian Li Beoka Medical Technology Co ranks #422 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, SiChuan Qian Li Beoka Medical Technology Co has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SiChuan Qian Li Beoka Medical Technology Co's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SiChuan Qian Li Beoka Medical Technology Co ranks #422 out of 853 companies for ROA %. This puts SiChuan Qian Li Beoka Medical Technology Co in the upper half of its industry. The industry median ROA % is 0.73. SiChuan Qian Li Beoka Medical Technology Co's value of 0.31% is 57.5% below this benchmark. Historically, SiChuan Qian Li Beoka Medical Technology Co's own ROA % has ranged from 0.57 to 54.56 over the past decade. While the company's 10-year median is 9.40 vs. the industry median of 0.73, SiChuan Qian Li Beoka Medical Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.73, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SiChuan Qian Li Beoka Medical Technology Co's current ROA % of 0.31% is 57.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on SiChuan Qian Li Beoka Medical Technology Co and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SiChuan Qian Li Beoka Medical Technology Co's current ROA % is 0.31%, which is 97% below median its own 10-year median of 9.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SiChuan Qian Li Beoka Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, SiChuan Qian Li Beoka Medical Technology Co (BJSE:920199) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.98, compared to a current price of ¥27.12 — trading 50.8% above its estimated fair value. The current ROA % is 0.31%, which is 97% below median its 10-year median of 9.40 and 57.5% below the Medical Devices & Instruments industry median of 0.73. SiChuan Qian Li Beoka Medical Technology Co's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For SiChuan Qian Li Beoka Medical Technology Co (BJSE:920199), the current ROA % is 0.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SiChuan Qian Li Beoka Medical Technology Co (BJSE:920199) Overvalued in 2026?
Based on GuruFocus' analysis, SiChuan Qian Li Beoka Medical Technology Co stock appears to be overvalued.
The current stock price of ¥27.12 is trading 50.8% above its estimated GF Value™ of ¥17.98.
GuruFocus considers SiChuan Qian Li Beoka Medical Technology Co to be Significantly Overvalued.
Key valuation signals for BJSE:920199:
ROA %: 0.31% (97% below median its 10-year median of 9.40)
GF Value™: ¥17.98 vs. price of ¥27.12 (50.8% above fair value)
Industry Position: 57.5% below the Medical Devices & Instruments median (#422 of 853)
No single metric tells the full story. See the BJSE:920199 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SiChuan Qian Li Beoka Medical Technology Co Ltd is an intelligent rehabilitation equipment manufacturer integrating research, development, production, sales, and service. Its product series comprises the Electrotherapy series, Heat therapy series, Force therapy series, Spa series, and Oxygen therapy series.
57GF Score
Get the complete analysis for BJSE:920199
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920199 has been successfully added to your 
